Hormone Receptor-positive Breast Cancer
📧 Sign up to get email alerts when something new happens for Hormone Receptor-positive Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-07-18Clinical Trial Update: Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd
Real-world study evaluating post-resistance treatment strategies after CDK4/6 inhibitors, PIK3CA inhibitors, or trastuzumab deruxtecan in ad…
-
CLINICAL_TRIALS research · 2025-07-11Clinical Trial Update: A Study of the Body's Response to Exercise and a Plant-Based Diet in Overweight Postmenopausal Women With Breast Cancer [Phase 2]
This clinical trial update describes a Phase 2 study evaluating the body's response to exercise and a plant-based diet in overweight postmen…
-
CLINICAL_TRIALS trial_result · 2025-06-29Clinical Trial Update: A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.
This ClinicalTrials.gov update reports results from a completed Danish study of HR+/HER2- metastatic breast cancer patients treated with pal…
-
CLINICAL_TRIALS research · 2025-06-19Clinical Trial Update: A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer [Phase 3]
Phase III trial evaluating ESG401 for locally advanced or metastatic HR+/HER2- breast cancer; the study is currently recruiting.
-
CLINICAL_TRIALS research · 2025-06-15Clinical Trial Update: A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients [Phase 2]
A Phase II clinical trial is evaluating HLX22 in combination with trastuzumab deruxtecan for HER2-low, hormone receptor-positive breast canc…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-06-05Clinical Trial Update: Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy [Phase 2]
This entry notes a Phase 2 clinical trial evaluating preoperative elacestrant in combination with PULSAR radiotherapy for hormone receptor-p…
-
CLINICAL_TRIALS research · 2025-06-05Clinical Trial Update: BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors [Phase 1]
Phase 1 clinical trial update for BGB-43395, evaluating it alone or in combination therapies in Chinese participants with HR+/HER2- breast c…
-
CLINICAL_TRIALS trial_result · 2025-05-31Clinical Trial Update: Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer [Phase 1]
A Phase 1 trial evaluating ribociclib in combination with PDR001 for metastatic hormone-receptor-positive (HR+) breast cancer, HER2-negative…
-
CLINICAL_TRIALS research · 2025-05-18Clinical Trial Update: Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04) [Phase 3]
A Phase III randomized trial evaluating neoadjuvant chemotherapy in combination with toripalimab for hormone receptor-positive, HER2-negativ…
-
CLINICAL_TRIALS research · 2025-05-07Clinical Trial Update: Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies. [Phase 2]
Phase 2 clinical trial evaluating whether infrared laser spectroscopy analysis of liquid biopsies can predict the efficacy of palbociclib in…
-
CLINICAL_TRIALS trial_result · 2025-05-04Clinical Trial Update: Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy [Phase 2]
Phase 2 clinical trial assessing albumin-bound sirolimus in combination with endocrine therapy for HR+/HER2- advanced/metastatic breast canc…
-
CLINICAL_TRIALS research · 2025-04-15Clinical Trial Update: TH1902 in Patients With Advanced Solid Tumors [Phase 1]
This is a Phase 1 clinical trial update for TH1902 in patients with advanced solid tumors. The study is currently active/not recruiting and …
-
CLINICAL_TRIALS trial_result · 2025-04-04Clinical Trial Update: PRE-I-SPY Phase I/Ib Oncology Platform Program [Phase 1]
Pre-I-SPY Phase I/Ib oncology platform program update with Phase 1 recruitment ongoing across multiple breast cancer indications, including …
-
CLINICAL_TRIALS research · 2025-03-04Clinical Trial Update: A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer [NA]
This clinical trial is evaluating sirolimus albumin-bound in combination with palbociclib and fulvestrant for advanced HR-positive, HER2-neg…
-
CLINICAL_TRIALS trial_result · 2025-02-27Clinical Trial Update: Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer [Phase 2]
Phase 2 clinical trial update evaluating correlation between clinical response and pathologic response in patients with early breast cancer.
-
FDA approval · 2025-02-11FDA Approved: KISQALI FEMARA CO-PACK — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application to offer a Kisqali-Femara co-pack, combining ribociclib with letrozole. The co-pack is intended …
-
CLINICAL_TRIALS trial_result · 2025-02-06Clinical Trial Update: WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor [Phase 1]
A Phase 1 study evaluating the three-drug combination bosutinib, palbociclib, and fulvestrant for HR-positive, HER2-negative metastatic brea…
-
CLINICAL_TRIALS research · 2025-02-03Clinical Trial Update: Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study
PALMARES-2 is a multicenter Italian study evaluating the ability to predict outcomes for patients with advanced HR-positive, HER2-negative b…
-
CLINICAL_TRIALS research · 2024-12-27Clinical Trial Update: Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer [Phase 2]
A Phase 2 clinical trial is evaluating chidamide in combination with angiogenesis inhibitors and fulvestrant for advanced HR-positive, HER2-…
-
CLINICAL_TRIALS trial_result · 2024-12-20Clinical Trial Update: Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating SHR-A1921 in combination with Adebrelimab for advanced hormone-receptor-positive, HER2-negative breast can…
-
CLINICAL_TRIALS research · 2024-12-16Clinical Trial Update: Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .
A recruiting clinical trial evaluating anlotinib-based combination therapy for hormone receptor-positive metastatic breast cancer, sponsored…
-
CLINICAL_TRIALS research · 2024-11-29Clinical Trial Update: Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial [Phase 2]
Phase II neoadjuvant trial assessing pyrotinib in combination with chemotherapy for HER2-low-expressing, hormone receptor-positive breast ca…
-
CLINICAL_TRIALS research · 2024-11-19Clinical Trial Update: A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors [Phase 1]
Phase 1 study evaluating XL092 as a single-agent and combination therapy for solid tumors, including renal cell carcinoma, hormone receptor-…
-
CLINICAL_TRIALS trial_result · 2024-11-08Clinical Trial Update: A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer [Phase 1]
This is a Phase 1 trial evaluating ipatasertib plus palbociclib and fulvestrant versus placebo plus palbociclib and fulvestrant in hormone r…
-
CLINICAL_TRIALS trial_result · 2024-11-07Clinical Trial Update: CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO [Phase 2]
Phase 2 trial comparing a CDK4/6 inhibitor with endocrine therapy to chemotherapy with endocrine therapy in advanced/metastatic breast cance…